Dianthus Therapeutics Inc SEC Filings

Dianthus Therapeutics filed an 8-K stating it furnished a press release with financial results for the quarter ended September 30, 2025. The release is attached as Exhibit 99.1. The information is furnished under Item 2.02 and is not deemed filed under Section 18, nor incorporated by reference except if specifically referenced.

Dianthus Therapeutics (DNTH) filed an 8-K to announce it has posted an updated corporate presentation on its investor relations website. The presentation is furnished as Exhibit 99.1 and is incorporated by reference.

The company notes the presentation contains forward-looking statements and includes cautionary language directing readers to related risk considerations. This is an informational update and does not disclose transaction terms or financial results.

Dianthus Therapeutics entered a License and Collaboration Agreement with Nanjing Leads Biolabs, securing exclusive rights outside Greater China to develop and commercialize DNTH212 (LBL-047), an investigational bifunctional fusion protein that targets pDC BDCA2 to reduce Type 1 interferon while inhibiting BAFF/APRIL to suppress B-cell function.

Consideration includes up to $38 million, comprised of $30 million in upfront and near‑term milestone payments and an additional $8 million milestone payable at the initiation of a Dianthus‑led Phase 1 study, at the company’s election in cash or stock. Leads may earn up to $962 million in development, regulatory, and sales milestones across five indications, plus tiered royalties from mid‑single digits up to low double‑digit on ex‑Greater China net sales.

A joint steering committee will oversee DNTH212; Leads can participate in global studies and enroll patients in Greater China and will cover certain related costs. The parties agreed to non‑competition outside Greater China. Dianthus reported approximately $555 million in cash, cash equivalents, and investments as of September 30, 2025, and $525 million pro forma after deducting near‑term and upfront payments.

Marino Garcia, who serves as CEO and President and a director of Dianthus Therapeutics, Inc. (DNTH), was awarded a stock option on 09/30/2025 to purchase 120,000 shares of the company's common stock at an exercise price of $39.35 per share. The option is exercisable through 09/30/2035 and will vest in equal monthly installments over the four years following the grant, subject to the reporting person’s continued service. After the grant the reporting person beneficially owns 120,000 shares underlying the option on a direct basis.

Ryan Savitz, Chief Financial Officer and Chief Business Officer of Dianthus Therapeutics, Inc. (DNTH), was granted a stock option on September 23, 2025 to purchase 60,000 shares of common stock at an exercise price of $37.87 per share. The option vests in equal monthly installments over four years beginning on the grant date and expires on September 23, 2035. The reporting on Form 4 was signed by an attorney-in-fact on September 25, 2025. The award is reported as a direct beneficial ownership of 60,000 underlying shares immediately following the transaction.

Dianthus Therapeutics insider grant: Simrat Randhawa, Chief Medical Officer of Dianthus Therapeutics (DNTH), was granted a stock option on 09/23/2025 to purchase 60,000 shares of common stock. The option has an exercise/conversion price of $37.87 per share and an exercise/expiration date of 09/23/2035. The award vests in equal monthly installments over four years starting 09/23/2025, subject to continued service. The filing reports the holdings as 60,000 shares held directly following the transaction and is signed on behalf of the reporting person by an attorney-in-fact.

Fairmount Funds Management and affiliated entities reported beneficial voting and dispositive power over 4,052,052 shares of Dianthus Therapeutics, Inc. (DNTH), representing 9.9% of the outstanding common stock based on 40,561,085 shares as of September 11, 2025. The position includes 3,307,191 shares of common stock and pre-funded warrants exercisable for up to 744,861 shares subject to a 9.99% beneficial ownership limitation. On September 11, 2025, Fairmount Healthcare Fund II L.P. purchased 600,000 shares in the company’s underwritten public offering at $33.00 per share for aggregate consideration of $19,800,000. Tomas Kiselak resigned from the Board on March 4, 2025, and the Reporting Persons state they currently have no present plans to effect corporate actions, while reserving the right to review or change that position in the future.

Insider transactions at Dianthus Therapeutics (DNTH): Chief Financial & Business Officer Ryan Savitz executed and sold shares under a Rule 10b5-1 plan on 09/09/2025. He exercised a stock option to buy 20,000 shares at a $8.44 exercise price and simultaneously sold 20,000 shares at $35 per share. After these transactions, the reporting person beneficially owns 104,766 shares of common stock. The option award underlying the exercise vests over time, with 25% vested on 06/02/2023 and the remainder vesting monthly over the following three years. The filing was signed by an attorney-in-fact on 09/11/2025.